Abstract
As there are several thousands of rare disorders and only some tents of orphan drugs authorized in Europe, off-label use of medicinal products occurs frequently in the diagnosis, prevention and treatment of rare diseases. Off-label use is the use of a medicinal product for another indication, another patient group, another dose or by another route of administration as indicated in the package insert. This so-called off-label use is suggested by a similar mode of action or a similar pathology. The competent authorities complain about this therapeutic usage because there is no evidence of their safety and efficacy. Payers hesitate to reimburse this non-validated use. The only responsible person for this use is the prescriber. Sometimes the patient will be asked to sign an informed consent. Normalization of this off-label use can only be done by the sponsor not by the medical profession or the patient organization. Pharmaceutical companies are not allowed to mention the off-label use to the medical profession: recently settlements are reached against companies to resolve allegations of off-label promotion of their orphan pharmaceutical products (Tobi, Trisenox, Xyrem). Some pharmaceutical companies bring the old substance on the market as a so-called new “repurposed” or “rediscovered” medicinal product with a higher price (Litak, Quenobilan, Savene, Xenbilox). When the medicinal product is taken from the market (deflazacort, mexiletine) the off-label users lose their only treatment. At the faculty of pharmacy of the University in Leuven, a group of students performed in-depth interviews to all the stakeholders in this process and identified the main obstacles to regularization. The Belgian Health Care Knowledge Center [https://kce.fgov.be/] will further explore these recommendations and give advice to the public authorities to take further actions. The Belgian Minister of Health already proposed a Royal Decree to reimburse some off-label use under restricted circumstances such as “unmet medical need”. EURORDIS has launched an off-label questionnaire within their members to explore the impact of this off-label prescribing for patients with rare diseases: http://www.ataxia.org.uk/news.php/234/off-label-use-of-medicines-information-needed-from-people-with-ataxia.
Highlights
As there are several thousands of rare disorders and only some tents of orphan drugs authorized in Europe, off-label use of medicinal products occurs frequently in the diagnosis, prevention and treatment of rare diseases
Off-label use is the use of a medicinal product for another indication, another patient group, another dose or by another route of administration as indicated in the package insert
Sometimes the patient will be asked to sign an informed consent. Normalization of this off-label use can only be done by the sponsor not by the medical profession or the patient organization
Summary
As there are several thousands of rare disorders and only some tents of orphan drugs authorized in Europe, off-label use of medicinal products occurs frequently in the diagnosis, prevention and treatment of rare diseases. Understanding off-label use and the new challenges Marc Dooms From 7th European Conference on Rare Diseases and Orphan Products (ECRD 2014) Off-label use is the use of a medicinal product for another indication, another patient group, another dose or by another route of administration as indicated in the package insert.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.